Arctigenin Inhibits Liver Cancer Tumorigenesis by Inhibiting Gankyrin Expression via C/EBPα and PPARα
​
The principal active component of burdock is arctigenin, which shows a range of bioactivities in vivo and in vitro. This study investigates the anti-tumor effects of arctigenin using two human liver cancer cell lines, HepG2 and Hep3B. Gankyrin, an oncoprotein, increases tumor growth and promotes metastasis and is present in high levels in cancerous HepG2 cells. This study demonstrated that arctigenin efficiently inhibited liver cancer cell growth in vitro in HepG2 cells and Hep3B cells and suggests that it plays a role in inhibiting tumor growth.
​
​
Published:
​
Frontiers in Pharmacology 9 -2018 P268 ISSN=1663-9812
​
​
Attribution:
​
Sun Ying¹ ², Tan Yu-jun¹ ᶟ, Lu Zhan-zhao¹ ², Li Bing-bing¹ ᶟ, Sun Cheng-hong¹ ᶟ, Li Tao¹ ᶟ, Zhao Li-li¹ ², Liu Zhong¹ ² ᶟ, Zhang Gui-min¹ ² ᶟ, Yao Jing-chun¹ ² ᶟ, Li Jie¹ ᶟ ¹Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Co., Ltd., Linyi, china, ²State Key Laboratory of Generic Manufacture technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co., Ltd., Linyi, China, ᶟCenter for New Drug Safety Evaluation of Lunan Pharmaceutical, Lunan Pharmaceutical Group Co., Ltd., Linyi, China
​
​